Marker Therapeutics, Inc.

Monthly Archives: February 2015

TapImmune Appoints John Bonfiglio as Strategic Advisor

Accomplished Biotech CEO to provide Capital Market, Financing and Drug Development Expertise SEATTLE, Feb. 25, 2015 – TapImmune Inc. (TPIV) has pleasure in announcing the appointment of John Bonfiglio, Ph.D., MBA as a Strategic Advisor.
Read More

TapImmune Appoints Patrick D. Yeramian, MD, Consulting Medical Director to Lead Phase II Clinical Trials in Triple Negative Breast and HER2/neu Breast Cancer

SEATTLE, Feb. 23, 2015 – TapImmune, (TPIV), an immunotherapy company specializing in the development of immunotherapeutics for the treatment of cancer including metastatic disease, is pleased to announce Patrick D. Yeramian, MD, MBA, has been appointed Consulting Medical Director.
Read More

TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015

TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015 Seattle, WA – February 20, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today Dr.
Read More

TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations

TapImmune Selects PCG Advisory Group for Investor Public and Social Media Relations Seattle, WA & NY, NY – February 19, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today the Company’s management team has selected New York City based PCG Advisory (PCG) as agency of record for Investor, Public, and Social Media Relations.
Read More